达拉非尼联合曲美替尼治疗BRAF突变肿瘤的发热特征
汇总4项临床试验1076例接受达拉非尼联合曲美替尼治疗的BRAF突变肿瘤患者,61.3%出现发热,5.7%为3/4级发热,15.6%发生方案定义的严重发热事件;发热多发生于治疗早期并随时间推移减少,暂时性剂量中断是最常见且有效的管理策略。
要点
- 达拉非尼联合曲美替尼治疗患者发热发生率61.3%,3/4级发热5.7%。
- 发热最高发于治疗早期,随治疗时间延长而下降。
- 暂时性剂量中断是最常见且有效的发热管理策略。
核心结论
- 发热是达拉非尼联合曲美替尼治疗最常见的不良事件,但可通过剂量中断进行管理。
研究设计与样本
- 汇总分析4项临床试验共1076例接受达拉非尼联合曲美替尼治疗的BRAF突变肿瘤患者。
- 纳入试验包括晚期NSCLC II期注册研究(N=82)、可切除III期黑色素瘤III期COMBI-AD研究(N=435)以及不可切除或转移性黑色素瘤III期COMBI-d研究(N=209)和COMBI-v研究(N=350)。
主要发现
- 1076例患者中61.3%发生发热,5.7%发生3/4级发热,15.6%发生方案定义的严重发热事件。
- 660例发热患者中33.0%发生1次、19.8%发生2次、47.1%发生≥3次发热。
- 发热发生率在治疗早期最高,随治疗时间延长而降低。
关键数值与推荐
- 发热发生率61.3%,3/4级发热发生率5.7%,方案定义严重发热事件发生率15.6%。
- 660例发热患者中1次、2次、≥3次发热的比例分别为33.0%、19.8%、47.1%。
临床怎么用
- 对接受达拉非尼联合曲美替尼治疗的患者应警惕发热,尤其在治疗早期。
- 暂时性剂量中断是发热最常见且有效的管理策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dabrafenib plus trametinib has demonstrated clinical benefit across multiple BRAF-mutant tumours, leading to approval for resected stage III and metastatic melanoma, non-small-cell lung cancer (NSCLC) and anaplastic thyroid cancer. Pyrexia is a common adverse event in patients treated with dabrafenib plus trametinib. Here, we characterise the incidence, patterns and management of pyrexia in patients receiving dabrafenib plus trametinib in clinical trials. METHODS: Patients (N = 1076) included in the analysis received dabrafenib plus trametinib in the following clinical trials: phase II registration trial in advanced NSCLC (N = 82), phase III COMBI-AD study in resectable stage III melanoma (N = 435) and phase III COMBI-d and COMBI-v studies in unresectable or metastatic melanoma (N = 209 and N = 350, respectively). RESULTS: Among the 1076 patients enrolled in the clinical trials, 61.3% developed pyrexia, 5.7% developed grade 3/4 pyrexia and 15.6% developed a protocol-defined serious pyrexia event. Among the 660 patients with pyrexia, 33.0% had 1 occurrence, 19.8% had 2 occurrences and 47.1% had ≥3 occurrences. The incidence of pyrexia was highest early in treatment and decreased with time on treatment. Temporary dose interruption of dabrafenib or trametinib was the most common and effective management strategy. CONCLUSIONS: Pyrexia is the most common adverse event associated with dabrafenib plus trametinib but is manageable with dose interruption. TRIAL REGISTRATION: ClinicalTrials.gov (Phase II NSCLC, NCT01336634; COMBI-AD, NCT01682083; COMBI-d, NCT01584648; COMBI-v, NCT01597908).
引用
- Schadendorf D, Robert C, Dummer R, et al. Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. Eur J Cancer. 2021. PMID: 34225229. doi:10.1016/j.ejca.2021.05.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。